The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):



	Three Months Ended September 30,				Nine Months Ended September 30,
Businesses	2018		2017		2018		2017
Endoscopy
U.S.	$	247	$	220	$	724	$	659
International	196		183		580		521
Worldwide	443		403		1,304		1,182

Urology and Pelvic Health
U.S.	214		190		623		569
International	89		84		280		246
Worldwide	303		274		904		815

Cardiac Rhythm Management
U.S.	289		275		869		845
International	186		188		594		562
Worldwide	475		463		1,462		1,407

Electrophysiology
U.S.	37		34		111		101
International	39		37		119		101
Worldwide	76		71		230		201

Neuromodulation
U.S.	155		126		446		367
International	34		28		113		82
Worldwide	189		154		559		449

Interventional Cardiology
U.S.	283		271		859		830
International	332		318		1,062		953
Worldwide	615		589		1,922		1,784

Peripheral Interventions
U.S.	152		141		449		429
International	142		127		436		375
Worldwide	293		268		885		802

Total Company
U.S.	1,375		1,257		4,078		3,798
International	1,018		965		3,184		2,839
Net Sales	$	2,393	$	2,222	$	7,262	$	6,640



	Three Months Ended September 30,				Nine Months Ended September 30,
Geographic Regions	2018		2017		2018		2017
U.S.	$	1,375	$	1,257	$	4,078	$	3,798
EMEA (Europe, Middle East and Africa)	498		474		1,619		1,411
APAC (Asia-Pacific)	425		401		1,282		1,165
LACA (Latin America and Canada)	94		91		282		264
	$	2,393	$	2,222	$	7,262	$	6,640

Emerging Markets (1)	$	263	$	236	$	794	$	671


(1)	Emerging Markets is defined as certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets.